Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Schwab

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Pathology Oncology Research : POR|January 1, 1997
MYCN Amplification in Neuroblastoma: a Paradigm for the Clinical Use of an OncogeneManfred Schwab
Cancer Letters|March 12, 2004
MYCN in neuronal tumoursManfred Schwab
Annals of the New York Academy of Sciences|July 4, 2002
Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncologyManfred Schwab
Cancer Letters|July 20, 2002
Genetic parameters of neuroblastomasFrank Westermann, Manfred Schwab
Cancer Letters|December 6, 2001
BRCA2: a genetic risk factor for breast cancerManfred Schwab, Andreas Claas, Larissa Savelyeva
Oncogene|July 25, 2003
Aflatoxin B1 aldehyde reductase (AFAR) genes cluster at 1p35-1p36.1 in a region frequently altered in human tumour cellsChristian Praml, Larissa Savelyeva, Manfred Schwab
Cancer Letters|December 5, 2006
Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cellsTobias Paffhausen, Manfred Schwab, Frank Westermann
Annals of the New York Academy of Sciences|January 15, 2005
Common fragile sites and cancer: targeted cloning by insertional mutagenesisIsabel Büttel, Anne Fechter, Manfred Schwab
Cancer Research|September 18, 2002
Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivoSabine Zitzmann, Volker Ehemann, Manfred Schwab
Cancer Letters|December 20, 2002
Preferential integration of a transfected marker gene into spontaneously expressed fragile sites of a breast cancer cell lineIsabel Matzner, Larissa Savelyeva, Manfred Schwab
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Pathology Oncology Research : POR|January 1, 1997
MYCN Amplification in Neuroblastoma: a Paradigm for the Clinical Use of an OncogeneManfred Schwab
Cancer Letters|March 12, 2004
MYCN in neuronal tumoursManfred Schwab
Annals of the New York Academy of Sciences|July 4, 2002
Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncologyManfred Schwab
Cancer Letters|July 20, 2002
Genetic parameters of neuroblastomasFrank Westermann, Manfred Schwab
Cancer Letters|December 6, 2001
BRCA2: a genetic risk factor for breast cancerManfred Schwab, Andreas Claas, Larissa Savelyeva
Oncogene|July 25, 2003
Aflatoxin B1 aldehyde reductase (AFAR) genes cluster at 1p35-1p36.1 in a region frequently altered in human tumour cellsChristian Praml, Larissa Savelyeva, Manfred Schwab
Cancer Letters|December 5, 2006
Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cellsTobias Paffhausen, Manfred Schwab, Frank Westermann
Annals of the New York Academy of Sciences|January 15, 2005
Common fragile sites and cancer: targeted cloning by insertional mutagenesisIsabel Büttel, Anne Fechter, Manfred Schwab
Cancer Research|September 18, 2002
Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivoSabine Zitzmann, Volker Ehemann, Manfred Schwab
Cancer Letters|December 20, 2002
Preferential integration of a transfected marker gene into spontaneously expressed fragile sites of a breast cancer cell lineIsabel Matzner, Larissa Savelyeva, Manfred Schwab
Pageof 7